SEARCH
Search Details
OKANO TakaichiGraduate School of Medicine / Faculty of Medical SciencesAssociate Professor
Research activity information
■ Paper- OBJECTIVE: We aimed to identify the impact of rheumatoid factor (RF) or anti-cyclic citrullinated peptide antibody (ACPA) titers on the retention of biological disease-modifying antirheumatic drugs (bDMARDs) and Janus kinase inhibitors (JAKi) in patients with rheumatoid arthritis. METHODS: We retrospectively analyzed 5312 courses of bDMARDs or JAKi from the ANSWER cohort. To calculate hazard ratios (HRs) for treatment discontinuation, we used multivariate Cox proportional hazards modeling, adjusted for potential confounders. RESULTS: HRs for discontinuation due to ineffectiveness were calculated based on RF classification, revealing that anti-interleukin-6 receptor antibodies (aIL-6R) exhibited the highest retention rates regardless of RF titer. In the RF-positive group, tumor necrosis factor inhibitors (TNFi) showed lower retention rates, whereas cytotoxic T lymphocyte-associated antigen-4-Ig (CTLA4-Ig) and JAKi followed aIL-6R in the retention rates. When classified based on ACPA, aIL-6R also exhibited the highest retention rates across all ACPA groups. TNFi showed lower retention rates compared with other agents in the ACPA-positive group, whereas CTLA4-Ig showed lower retention rates in the ACPA-negative group compared with other agents. CONCLUSION: Considering effectiveness, aIL-6R showed the highest retention rates regardless of seropositivity. Although CTLA4-Ig and JAKi followed aIL-6R in RF or ACPA-positive cases, CTLA4-Ig showed the lowest retention rates in ACPA-negative cases.Mar. 2025, Modern rheumatology, English, International magazineScientific journal
- Oct. 2024, RheumatologyScientific journal
- The mechanisms responsible for the distribution and severity of joint involvement in rheumatoid arthritis (RA) are not known. To explore whether site-specific FLS biology might be associated with location-specific synovitis and explain the predilection for hand (wrist/metacarpal phalangeal joints) involvement in RA, we generated transcriptomic and chromatin accessibility data from FLS to identify the transcription factors (TFs) and pathways. Networks were constructed by integration of chromatin accessibility and gene expression data. Analysis revealed joint-specific patterns of FLS phenotype, with proliferative, migratory, proinflammatory, and matrix-degrading characteristics observed in resting FLS derived from the hand joints compared with hip or knee. TNF-stimulation amplified these differences, with greater enrichment of proinflammatory and proliferative genes in hand FLS compared with hip and knee FLS. Hand FLS also had the greatest expression of markers associated with an 'activated' state relative to the 'resting' state, with the greatest cytokine and MMP expression in TNF-stimulated hand FLS. Predicted differences in proliferation and migration were biologically validated with hand FLS exhibiting greater migration and cell growth than hip or knee FLS. Distinctive joint-specific FLS biology associated with a more aggressive inflammatory response might contribute to the distribution and severity of joint involvement in RA.May 2024, JCI insightScientific journal
- OBJECTIVES: This multicentre, retrospective study aimed to compare retention and reasons for discontinuation between Janus kinase inhibitors (JAKi) and biologic disease-modifying antirheumatic drugs in patients with elderly-onset rheumatoid arthritis (EORA). METHODS: Patients with RA enrolled in a Japanese multicentre observational registry between 2015 and 2022 were included. EORA was defined as RA with onset at 60 or over. To adjust confounding factors by indication for initiation of tumor necrosis factor inhibitors (TNFi), interleukin-6 inhibitors (IL-6i), cytotoxic T-lymphocyte associated antigen 4 immunoglobulin (CTLA4-Ig) blockers, or JAKi, a propensity score based on baseline characteristics was used to compare drug retention. To assess the reasons for discontinuation, retention rates for ineffectiveness, adverse events, and remission were analyzed as secondary outcomes. RESULTS: A total of 572 patients with 835 treatment courses were identified (314 TNFi, 175 IL-6i, 228 CTLA4-Ig, and 118 JAKi). After adjusting for differences in baseline characteristics, drug retention was significantly higher for IL-6i (HR = 0.38, 95%CI = 0.27-0.55, p< 0.01) as compared with TNFi. Discontinuation due to lack of effectiveness was lower with the JAKi (HR = 0.38, 95%CI = 0.22-0.66, p< 0.01) and the IL-6i (HR = 0.29, 95%CI = 0.19-0.46, p< 0.01) as compared with the TNFi although the CTLA4-Ig had a similar HR to TNFi. The adjusted incidence of discontinuation due to adverse event was higher in the JAKi (HR = 2.86, 95%CI = 1.46-5.59, p< 0.01) than the TNFi. CONCLUSIONS: In EORA patients, IL-6i and JAKi had longer retention and less discontinuation due to ineffectiveness than TNFi. The potential risks of JAKi should be approached with an individualized perspective.Feb. 2024, Rheumatology (Oxford, England), English, International magazineScientific journal
- OBJECTIVE: This multicentre, retrospective study compared the efficacy and safety of tofacitinib, baricitinib, peficitinib and upadacitinib in real-world clinical settings after minimizing selection bias and adjusting the confounding patient characteristics. METHOD: The 622 patients were selected from the ANSWER cohort database and treated with tofacitinib (TOF), baricitinib (BAR), peficitinib (PEF) or upadacitinib (UPA). The patient's background was matched using propensity score-based inverse probability of treatment weighting (IPTW) among four treatment groups. The values of Clinical Disease Activity Index (CDAI), C-reactive protein (CRP), and modified Health Assessment Questionnaire (mHAQ) after drug initiation and the remission or low disease activity (LDA) rates of CDAI at 6 months after drug initiation were compared among the four groups. Further, the predictive factor for TOF and BAR efficacy was analysed. RESULTS: The retention and discontinuation rates until 6 months after drug initiations were not significantly different among the four JAK inhibitors treatment groups. Mean CDAI value, CDAI remission rate, and CDAI-LDA rate at 6 months after drug initiation were not significantly different among treatment groups. Baseline CDAI (TOFA: OR 1.09, P < 0.001; BARI: OR 1.07, P < 0.001), baseline CRP (TOFA: OR 1.32, P = 0.049), baseline glucocorticoid dose (BARI: OR 1.18, 95% CI 1.01-1.38, P = 0.035), a number of previous biological or targeted synthetic disease-modifying antirheumatic drugs (biological/targeted synthetic DMARDs) (BARI: OR 1.36, P = 0.004) were predictive factors for resistance to CDAI-LDA achievement to JAK inhibitor treatment. CONCLUSION: The efficacy and safety of TOF, BAR, PEF and UPA were not significantly different for the treatment of patients with rheumatoid arthritis.Nov. 2023, Rheumatology (Oxford, England), English, International magazineScientific journal
- OBJECTIVES: This multicentre retrospective study in Japan aimed to assess the retention of biological disease-modifying antirheumatic drugs and Janus kinase inhibitors (JAKi), and to clarify the factors affecting their retention in a real-world cohort of patients with rheumatoid arthritis. METHODS: The study included 6666 treatment courses (bDMARD-naïve or JAKi-naïve cases, 55.4%; tumour necrosis factor inhibitors (TNFi) = 3577; anti-interleukin-6 receptor antibodies (aIL-6R) = 1497; cytotoxic T lymphocyte-associated antigen-4-Ig (CTLA4-Ig) = 1139; JAKi=453 cases). The reasons for discontinuation were divided into four categories (ineffectiveness, toxic adverse events, non-toxic reasons and remission); multivariate Cox proportional hazards modelling by potential confounders was used to analyse the HRs of treatment discontinuation. RESULTS: TNFi (HR=1.93, 95% CI: 1.69 to 2.19), CTLA4-Ig (HR=1.42, 95% CI: 1.20 to 1.67) and JAKi (HR=1.29, 95% CI: 1.03 to 1.63) showed a higher discontinuation rate due to ineffectiveness than aIL-6R. TNFi (HR=1.28, 95% CI: 1.05 to 1.56) and aIL-6R (HR=1.27, 95% CI: 1.03 to 1.57) showed a higher discontinuation rate due to toxic adverse events than CTLA4-Ig. Concomitant use of oral glucocorticoids (GCs) at baseline was associated with higher discontinuation rate due to ineffectiveness in TNFi (HR=1.24, 95% CI: 1.09 to 1.41), as well as toxic adverse events in JAKi (HR=2.30, 95% CI: 1.23 to 4.28) and TNFi (HR=1.29, 95%CI: 1.07 to 1.55). CONCLUSIONS: TNFi (HR=1.52, 95% CI: 1.37 to 1.68) and CTLA4-Ig (HR=1.14, 95% CI: 1.00 to 1.30) showed a higher overall drug discontinuation rate, excluding non-toxicity and remission, than aIL-6R.Aug. 2023, RMD open, 9(3) (3), English, International magazineScientific journal
- OBJECTIVES: Exosomes are potent vehicles for intercellular communication. Rheumatoid arthritis (RA) is a chronic systemic disease of unknown etiology. Local administration of miR-124 precursor to rats with adjuvant-induced arthritis suppresses systemic arthritis and bone destruction. Thus, exosomes may be involved in this disease. We aimed to determine the role of exosomes in the pathology of RA. METHODS: Fibroblast-like synoviocytes (FLS) were collected from patients with RA and osteoarthritis (OA). miR-124-3p mimic was transfected into the RA FLS (RA miR-124 FLS). Exosomes were collected from the culture medium by ultracentrifugation. Macrophages were produced from THP-1 cells. MicroRNAs in the exosomes were analyzed using real-time PCR. Proteomics analysis was performed using nanoscale liquid chromatography-tandem mass spectrometry. Macrophage migration was evaluated using a Transwell migration assay. SiRNA was used to knockdown proteins of interest. RESULTS: MicroRNAs in the RA FLS, RA miR-124 FLS, and OA FLS exosomes were similar. Proteomics analysis revealed that pentraxin 3 (PTX3) levels were higher in RA FLS exosomes than in RA miR-124 FLS and OA FLS exosomes, and proteasome 20S subunit beta 5 (PSMB5) levels were lower in RA FLS exosomes than in RA miR-124 FLS and OA FLS exosomes. The RA FLS exosomes promoted and the RA miR-124 FLS exosomes suppressed macrophage migration. PTX3-silenced RA FLS exosomes suppressed and PSMB5-silenced OA FLS exosomes promoted macrophage migration. CONCLUSIONS: RA FLS exosomes promote macrophage migration via PTX3 and PSMB5, and miR-124-3p suppresses this migration.Apr. 2023, Heliyon, 9(4) (4), e14986, English, International magazineScientific journal
- (一社)日本リウマチ学会, Mar. 2023, 日本リウマチ学会総会・学術集会プログラム・抄録集, 67回, 551 - 551, JapaneseJAK阻害薬-2 JAK阻害薬4剤の有効性比較と有効性に影響を与える因子の探索 関西多施設ANSWERコホートによる解析
- (一社)日本リウマチ学会, Mar. 2023, 日本リウマチ学会総会・学術集会プログラム・抄録集, 67回, 621 - 621, JapaneseJAK阻害薬-4 tsDMARDsとbDMARDsにより関節リウマチ患者の非炎症性疼痛へ及ぼす効果の比較 関西多施設共同研究ANSWER Cohortを用いた検討
- (一社)日本リウマチ学会, Mar. 2022, 日本リウマチ学会総会・学術集会プログラム・抄録集, 66回, 584 - 584, Japaneseアバタセプト継続率と血球分画の関連 ANSWERコホートを用いた研究
- (一社)日本リウマチ学会, Mar. 2022, 日本リウマチ学会総会・学術集会プログラム・抄録集, 66回, 376 - 376, Japanese関節リウマチの治療(csDMARDs) MTXの継続率と生活習慣病の関連 関西多施設ANSWERコホートを用いた検討
- Resolvins, are specialized pro-resolving mediators (SPMs) derived from n-3 polyunsaturated fatty acids. They contribute actively to the resolution of inflammation, but little is known concerning their role in chronic inflammation, such as in rheumatoid arthritis (RA). Here, we performed lipid mediator (LM) profiling in tissues from the paws of SKG arthritic mice using lipid chromatography (LC)/mass spectrometry (MS)/MS-based LM metabololipidomics. We found elevated levels of SPMs including resolvin D5 (RvD5) in these tissues. Moreover, RvD5 levels were significantly correlated with arthritis disease activity. From experiments to assess the role of RvD5 in the pathology of RA, we concluded that RvD5 suppressed Th17 cell differentiation and facilitated regulatory T cell differentiation, as well as inhibiting CD4+ T cell proliferation. Furthermore, RvD5 attenuated osteoclast differentiation and interfered with osteoclastogenesis. Targeting the resolution of inflammation could be promising as a novel treatment for RA.Aug. 2021, Scientific reports, 11(1) (1), 17312 - 17312, English, International magazineScientific journal
- OBJECTIVES: We aimed to identify disease-specific surface proteins on extracellular vesicles (EVs) as novel serum biomarkers of polymyositis and dermatomyositis (PM/DM). METHODS: We performed liquid chromatography-tandem mass spectrometry (LC/MS) on purified EVs from sera of 10 PM/DM, 23 patients with other autoimmune diseases and 10 healthy controls (HC). We identified membrane proteins preferentially present in EVs of PM/DM patients by bioinformatics and biostatistical analyses. We developed EV sandwich ELISA for directly detecting serum EVs expressing disease-specific membrane proteins and evaluated their clinical utility using sera of 54 PM/DM, 24 rheumatoid arthritis (RA), 20 systemic lupus erythematosus (SLE), 13 systemic sclerosis, 25 Duchenne and Becker muscular dystrophy (DMD/BMD) patients, and 36 HC. RESULTS: LC/MS analysis identified 1,220 proteins in serum EVs. Of these, Plexin D1 was enriched in those from PM/DM patients relative to HC or patients without PM/DM. Using a specific EV sandwich ELISA, we found that levels of Plexin D1-positive EVs (Plexin D1+ EVs) in serum were significantly greater in PM/DM patients than in HC, RA or SLE, or DMD/BMD patients. Serum levels of Plexin D1+ EVs were greater in those PM/DM patients with muscle pain or weakness. Serum levels of Plexin D1+ EVs were significantly correlated with levels of aldolase (rs=0.481), white blood cells (rs=0.381), neutrophils (rs=0.450), and platelets (rs=0.408) in PM/DM patients. Finally, serum levels of Plexin D1+ EVs decreased significantly in patients with PM/DM in clinical remission after treatment. CONCLUSION: We have identified levels of circulating Plexin D1+ EVs as a novel serum biomarker for PM/DM.Jul. 2021, Rheumatology (Oxford, England), 61(4) (4), 1669 - 1679, English, International magazineScientific journal
- (一社)日本リウマチ学会, Mar. 2021, 日本リウマチ学会総会・学術集会プログラム・抄録集, 65回, 381 - 381, JapaneseSLE・抗リン脂質抗体症候群(臨床):バイオマーカー 当院における抗DNA抗体検出法についての検討 Farr法とCLIA法の比較について
- (一社)日本リウマチ学会, Mar. 2021, 日本リウマチ学会総会・学術集会プログラム・抄録集, 65回, 612 - 612, Japanese異所性石灰化病変を合併した全身性エリテマトーデス患者に対してテリパラチドにより異所性石灰化と骨粗鬆症を同時に治療しえた一例
- (一社)日本リウマチ学会, Mar. 2021, 日本リウマチ学会総会・学術集会プログラム・抄録集, 65回, 381 - 381, JapaneseSLE・抗リン脂質抗体症候群(臨床):バイオマーカー 当院における抗DNA抗体検出法についての検討 Farr法とCLIA法の比較について
- (一社)日本リウマチ学会, Mar. 2021, 日本リウマチ学会総会・学術集会プログラム・抄録集, 65回, 612 - 612, Japanese異所性石灰化病変を合併した全身性エリテマトーデス患者に対してテリパラチドにより異所性石灰化と骨粗鬆症を同時に治療しえた一例
- 2021, Arthritis Research and Therapy, 23(1) (1), 133 - 133, English, International magazineScientific journal
- (一社)日本骨粗鬆症学会, Sep. 2020, 日本骨粗鬆症学会雑誌, 6(Suppl.1) (Suppl.1), 268 - 268, Japanese異所性石灰化病変を合併した全身性エリテマトーデス患者に対してテリパラチドにより異所性石灰化と骨粗鬆症を同時に治療しえた一例
- (一社)日本リウマチ学会, Aug. 2020, 日本リウマチ学会総会・学術集会プログラム・抄録集, 64回, 455 - 455, Japanese関節リウマチの治療評価と予測 Adalimumab寛解中止後の関節リウマチ症例における"BMI非Normal"の再燃リスクとしての可能性について
- (一社)日本リウマチ学会, Aug. 2020, 日本リウマチ学会総会・学術集会プログラム・抄録集, 64回, 634 - 634, Japanese間質性肺炎を有するRA患者におけるDMARDsの安全性に関する系統的レビュー
- (一社)日本リウマチ学会, Aug. 2020, 日本リウマチ学会総会・学術集会プログラム・抄録集, 64回, 636 - 636, Japanese悪性腫瘍を有するRA患者におけるDMARDsの安全性に関する系統的レビュー
- (一社)日本リウマチ学会, Aug. 2020, 日本リウマチ学会総会・学術集会プログラム・抄録集, 64回, 697 - 697, Japanese高用量ステロイド治療中の膠原病患者におけるニューモシスティス肺炎(PCP)予防薬の効果
- (一社)日本リウマチ学会, Aug. 2020, 日本リウマチ学会総会・学術集会プログラム・抄録集, 64回, 763 - 763, Japaneseステロイド、DMARDs加療中のRA患者へのワクチン接種の有効性、安全性に関する系統的レビュー
- (一社)日本リウマチ学会, Aug. 2020, 日本リウマチ学会総会・学術集会プログラム・抄録集, 64回, 634 - 634, Japanese間質性肺炎を有するRA患者におけるDMARDsの安全性に関する系統的レビュー
- (一社)日本リウマチ学会, Aug. 2020, 日本リウマチ学会総会・学術集会プログラム・抄録集, 64回, 636 - 636, Japanese悪性腫瘍を有するRA患者におけるDMARDsの安全性に関する系統的レビュー
- (一社)日本リウマチ学会, Aug. 2020, 日本リウマチ学会総会・学術集会プログラム・抄録集, 64回, 697 - 697, Japanese高用量ステロイド治療中の膠原病患者におけるニューモシスティス肺炎(PCP)予防薬の効果
- (一社)日本リウマチ学会, Aug. 2020, 日本リウマチ学会総会・学術集会プログラム・抄録集, 64回, 763 - 763, Japaneseステロイド、DMARDs加療中のRA患者へのワクチン接種の有効性、安全性に関する系統的レビュー
- A 72-year-old woman was referred to our institution with decompensated congestive heart failure owing to subacute severe aortic regurgitation and mitral regurgitation. Her blood sample tested positive for myeloperoxidase anti-neutrophil cytoplasmic antibody (ANCA). Cardiac computed tomography revealed abnormal thickening and shortening of the aortic valvar leaflets as well as wall thickening of the sinuses of Valsalva. Based on the diagnosis of ANCA-associated vasculitis, predominantly involving the aortic root, prednisolone administration was initiated, which failed to improve the valvar dysfunction. The patient underwent aortic root replacement and mitral annuloplasty. Histopathology confirmed severe inflammation involving both the aortic valvar sinuses and leaflets.Mar. 2020, Internal medicine (Tokyo, Japan), 59(5) (5), 663 - 671, English, Domestic magazine[Refereed]Scientific journal
- An 80-year-old woman with rheumatoid arthritis presented with chest pain. Clinical examination revealed new-onset paroxysmal atrial fibrillation with symptomatic sinus pauses and worsening mitral regurgitation, which were both resistant to conventional therapies. Based on her skin lesions, an increase in pleural and pericardial effusion, possible myocardial involvement, and a positive finding for immune complex testing, rheumatoid vasculitis was diagnosed. Subsequent glucocorticoid therapy suppressed systemic inflammation, resulting in structural, functional, and electrical reverse remodeling of the left atrium with complete remission of atrial arrhythmias and also an improvement of mitral regurgitation. This case highlights the importance of evaluating the underlying disease activity in a case of de novo paroxysmal atrial fibrillation associated with systemic autoimmune disease.2020, Internal Medicine, 58(21) (21), 3093 - 3098, English, Domestic magazine[Refereed]Scientific journal
- AIM:Subjective well-being (SWB) is a psychological construct that is synonymous with happiness. Many variables including age, sex, income, employment, and marital status are related to SWB. Health is also an important determinant of SWB that can be adversely affected in patients with chronic conditions such as rheumatoid arthritis (RA). In this study, we evaluate the SWB of RA patients and compare it with that of healthy controls. METHODS:We obtained the original dataset from the "Quality of Life Survey, 2013", which was conducted by the Economic and Social Research Institute, Cabinet Office, Government of Japan. In this survey, SWB was determined by asking participants to rate their happiness between 0 (very unhappy) and 10 (very happy). The survey also included a 56-point questionnaire regarding well-being-related variables. This questionnaire was administered to RA patients recruited from Kobe University Hospital, and clinical and treatment data were simultaneously collected. RESULTS:Multivariate analysis revealed that RA patients with high or moderate disease activity had SWB scores that were similar to those of controls. However, the SWB scores of RA patients in remission or with low disease activity were higher than those of controls (P = .013). SWB was associated with household income, self-assessment of living costs, self-assessment of health, depression/ anxiety, and social connection. CONCLUSIONS:For RA patients, achieving the therapeutic target can result in better SWB than that of healthy controls. Financial status, self-assessment of health, psychological stress, and social network are also important determinants for the SWB of RA patients.Oct. 2019, International journal of rheumatic diseases[Refereed]Scientific journal
- Glutamine metabolism and the mechanistic target of rapamycin (mTOR) pathway are activated cooperatively in the differentiation and activation of inflammatory immune cells. But the combined inhibition of both pathways was rarely investigated. This study investigated how inhibiting both glutamine metabolism with 6-diazo-5-oxo-L-norleucine (DON) and mTOR with rapamycin affects immune cells and the arthritis in a mouse model. We revealed that rapamycin and DON additively suppressed CD4+ T cell proliferation, and both of them inhibited Th17 cell differentiation. While DON inhibited the differentiation of dendritic cells and macrophages and facilitated that of Ly6G+ granulocytic (G)-MDSCs more strongly than did rapamycin, G-MDSCs treated with rapamycin but not DON suppressed CD4+ T cell proliferation in vitro. The combination of rapamycin and DON significantly suppressed the arthritis in SKG mice more strongly than did each monotherapy in vivo. The numbers of CD4+ T and Th17 cells in the spleen were lowest in mice treated with the combination therapy. Thus, combined treatment with rapamycin and DON additively ameliorated the arthritis in SKG mice, possibly by suppressing CD4+ T cell proliferation and Th17 differentiation. These results suggest the combination of rapamycin and DON may be a potential novel therapy for arthritis.Apr. 2019, Scientific reports, 9(1) (1), 6374 - 6374, English, International magazine[Refereed]Scientific journal
- Dec. 2018, The Journal of rheumatology[Refereed]Scientific journal
- Jul. 2018, Immunological Medicine, 41(3) (3), 89 - 97, English[Refereed]Scientific journal
- OBJECTIVE: SKG mice develop interstitial lung disease (ILD) resembling rheumatoid arthritis-associated ILD in humans. The aim of this study was to clarify the mechanism underlying the lung pathology by analyzing lung-infiltrating cells in SKG mice with ILD. METHODS: We assessed the severity of zymosan A (ZyA)-induced ILD in SKG mice histologically, and we examined lung-infiltrating cells by flow cytometry. Total lung cells and isolated monocytic myeloid-derived suppressor cells (MDSCs) were cultured in vitro with granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-4. The proliferation of 5,6-carboxyfluorescein diacetate N-succinimidyl ester-labeled naive T cells cocultured with isolated CD11b+Gr-1dim cells and MDSCs was evaluated by flow cytometry. CD11b+Gr-1dim cells were adoptively transferred to ZyA-treated SKG mice. RESULTS: MDSCs, Th17 cells, and group 1 and 3 innate lymphoid cells (ILC1s and ILC3s) were increased in the lungs; the proportion of these cells varied with ILD severity. In this process, we found that a unique cell population, CD11b+Gr-1dim cells, was expanded in the severely inflamed lungs. Approximately half of the CD11b+Gr-1dim cells expressed CD11c. CD11b+Gr-1dim cells were induced from monocytic MDSCs with GM-CSF in vitro and were considered tolerogenic because they suppressed T cell proliferation. These CD11b+Gr-1dim cells have never been described previously, and we termed them CD11b+Gr-1dim tolerogenic dendritic cell (DC)-like cells. Th17 cells, ILC1s, and ILC3s in the inflamed lung produced GM-CSF, which may have expanded CD11b+Gr-1dim tolerogenic DC-like cells in vivo. Furthermore, adoptive transfer of CD11b+Gr-1dim tolerogenic DC-like cells significantly suppressed progression of ILD in SKG mice. CONCLUSION: We identified unique suppressive myeloid cells that were differentiated from monocytic MDSCs in SKG mice with ILD, and we termed them CD11b+Gr-1dim tolerogenic DC-like cells.Wiley-Blackwell, Dec. 2017, Arthritis & rheumatology (Hoboken, N.J.), 69(12) (12), 2314 - 2327, English, International magazine[Refereed]Scientific journal
- Apr. 2017, ARTHRITIS RESEARCH & THERAPY, 19(1) (1), 76, English[Refereed]Scientific journal
- Feb. 2017, SCIENTIFIC REPORTS, 7, 42412, English[Refereed]Scientific journal
- May 2016, ARTHRITIS RESEARCH & THERAPY, 18(1) (1), English[Refereed]Scientific journal
- (一社)日本リウマチ学会, Mar. 2015, 日本リウマチ学会総会・学術集会プログラム・抄録集, 59回, 328 - 328, Japanese関節リウマチの病因・病態 血清メタボローム解析による関節リウマチの代謝プロファイルの解明および各種生物学的製剤投与後の代謝変動の解析
- (一社)日本臨床免疫学会, Aug. 2014, 日本臨床免疫学会会誌, 37(4) (4), 375 - 375, Japanese
- (一社)日本リウマチ学会, Mar. 2014, 日本リウマチ学会総会・学術集会プログラム・抄録集, 58回, 314 - 314, JapaneseIgG4関連疾患 当科におけるIgG4関連疾患が疑われた26例の臨床的検討(再燃例について)
- (一社)日本リウマチ学会, Mar. 2014, 日本リウマチ学会総会・学術集会プログラム・抄録集, 58回, 437 - 437, Japanese多発性筋炎・皮膚筋炎 当院における炎症性筋疾患(IIM)88例の治療経験
- (一社)日本リウマチ学会, Mar. 2014, 日本リウマチ学会総会・学術集会プログラム・抄録集, 58回, 559 - 559, Japanese心外膜炎で発症したIgG4関連疾患の一例
- (一社)日本リウマチ学会, Mar. 2014, 日本リウマチ学会総会・学術集会プログラム・抄録集, 58回, 715 - 715, Japaneseシェーグレン症候群患者の唾液メタボロミクス
- Informa Healthcare, Nov. 2013, Modern Rheumatology, 23(6) (6), 1192 - 1197, English[Refereed]Scientific journal
- Informa Healthcare, 2013, Scandinavian Journal of Rheumatology, 42(4) (4), 276 - 280, English[Refereed]Scientific journal
- (一社)日本リウマチ学会, Mar. 2023, 日本リウマチ学会総会・学術集会プログラム・抄録集, 67回, 574 - 574, Japaneseフレイルの現状と脱却への視点 関節リウマチ患者におけるHAQの経年的変化 ANSWERコホートより
- (一社)日本リウマチ学会, Mar. 2023, 日本リウマチ学会総会・学術集会プログラム・抄録集, 67回, 526 - 526, Japanese疫学1:RA/関節型JIAの治療 高齢関節リウマチ患者における疾患活動性の年次変化に関する検討 関西多施設共同研究ANSWER Cohort study
- (一社)日本リウマチ学会, Mar. 2022, 日本リウマチ学会総会・学術集会プログラム・抄録集, 66回, 584 - 584, Japaneseアバタセプト継続率と血球分画の関連 ANSWERコホートを用いた研究
- (一社)日本リウマチ学会, Mar. 2022, 日本リウマチ学会総会・学術集会プログラム・抄録集, 66回, 351 - 351, JapaneseJAK阻害薬:安全性 関節リウマチ患者における生物学的製剤とJAK阻害剤6666例の継続率と中止理由についての検討 関西多施設ANSWER cohortによる解析
- (一社)日本リウマチ学会, Mar. 2022, 日本リウマチ学会総会・学術集会プログラム・抄録集, 66回, 594 - 594, Japanese肥満度が関節リウマチにおける抗TNF製剤の治療効果に及ぼす影響 関西多施設ANSWERコホートを用いた検討
- Feb. 2021, ARTHRITIS & RHEUMATOLOGY, 72, English
- Oct. 2020, ARTHRITIS & RHEUMATOLOGY, 72, EnglishCombined Inhibition of Autophagy and Glutamine Metabolism Suppresses Cell Growth of RA Synoviocytes and Ameliorates Arthritis in SKG MiceSummary international conference
- Oct. 2020, ARTHRITIS & RHEUMATOLOGY, 72, EnglishSummary international conference
- Oct. 2019, ARTHRITIS & RHEUMATOLOGY, 71, EnglishThe Comparative Efficacy of Pneumocystis Pneumonia Prophylactic Regimens in Patients with Connective Tissue Diseases Receiving Prolonged High-dose GlucocorticoidsSummary international conference
- 日本臨床免疫学会, Oct. 2019, 日本臨床免疫学会総会プログラム・抄録集, 47回, 112 - 112, Japaneseベーチェット病に伴う仙腸関節炎に対して抗TNFα阻害薬で治療中に、食道穿通病変と回盲部潰瘍が出現し、内科的治療で治療しえた腸管型ベーチェット病の1例[Refereed]
- 日本臨床検査医学会, Oct. 2019, 臨床病理, 67(補冊) (補冊), 166 - 166, Japanese当院における全身性エリテマトーデスによる血球貪食症候群の検討[Refereed]
- 日本臨床免疫学会, Oct. 2019, 日本臨床免疫学会総会プログラム・抄録集, 47回, 112 - 112, Japaneseベーチェット病に伴う仙腸関節炎に対して抗TNFα阻害薬で治療中に、食道穿通病変と回盲部潰瘍が出現し、内科的治療で治療しえた腸管型ベーチェット病の1例
- Jun. 2019, ANNALS OF THE RHEUMATIC DISEASES, 78, 1559 - 1559, EnglishSummary international conference
- Jun. 2019, ANNALS OF THE RHEUMATIC DISEASES, 78, 1659 - 1659, EnglishSummary international conference
- (一社)日本リウマチ学会, Mar. 2019, 日本リウマチ学会総会・学術集会プログラム・抄録集, 63回, 428 - 428, Japaneseリウマチ性疾患の超音波検査 関節エコーを用いたアダリムマブ寛解休薬後の再燃予測についての多施設前向き研究 PROUD study
- (一社)日本リウマチ学会, Mar. 2019, 日本リウマチ学会総会・学術集会プログラム・抄録集, 63回, 623 - 623, Japaneseアダリムマブの寛解後休薬についての検討[Refereed]
- (一社)日本リウマチ学会, Mar. 2019, 日本リウマチ学会総会・学術集会プログラム・抄録集, 63回, 729 - 729, Japanese当施設におけるニューモシスティス肺炎に対する治療の実態[Refereed]
- (一社)日本リウマチ学会, Mar. 2019, 日本リウマチ学会総会・学術集会プログラム・抄録集, 63回, 735 - 735, JapaneseSLEとの鑑別を要した自己免疫性溶血性貧血と特発性膜性腎症の合併例[Refereed]
- (一社)日本リウマチ学会, Mar. 2019, 日本リウマチ学会総会・学術集会プログラム・抄録集, 63回, 758 - 758, Japanese関節リウマチとSLEを合併した強皮症オーバーラップ症候群の一例[Refereed]
- (一社)日本リウマチ学会, Mar. 2019, 日本リウマチ学会総会・学術集会プログラム・抄録集, 63回, 767 - 767, Japanese抗TIF1γ抗体陽性皮膚筋炎症例の臨床的特徴[Refereed]
- (一社)日本リウマチ学会, Mar. 2019, 日本リウマチ学会総会・学術集会プログラム・抄録集, 63回, 784 - 784, JapaneseANCA関連血管炎の寛解導入療法中に、リツキシマブに起因する急性血小板減少が疑われた3例[Refereed]
- 日本臨床免疫学会, Nov. 2018, 日本臨床免疫学会総会プログラム・抄録集, 46回, 83 - 83, Japanese顔面から頸部の表在感覚障害をきたしたIgA血管炎の1例[Refereed]
- 日本臨床免疫学会, Nov. 2018, 日本臨床免疫学会総会プログラム・抄録集, 46回, 110 - 110, Japanese顔面から頸部の表在感覚障害をきたしたIgA血管炎の1例[Refereed]
- 日本臨床免疫学会, Nov. 2018, 日本臨床免疫学会総会プログラム・抄録集, 46回, 138 - 138, Japaneseサイトメガロウイルス食道炎・胃炎による門脈ガス血症を来した多発血管炎性肉芽腫症[Refereed]
- (一社)日本性感染症学会, Sep. 2018, 日本性感染症学会誌, 29(1) (1), 144 - 144, JapaneseHIV感染症に合併した梅毒性乾癬の1例
- 日本皮膚科学会-大阪地方会・京滋地方会, Apr. 2018, 皮膚の科学, 17(2) (2), 120 - 121, JapaneseHIV感染症に合併した梅毒性乾癬の1例
- (一社)日本リウマチ学会, Mar. 2018, 日本リウマチ学会総会・学術集会プログラム・抄録集, 62回, 415 - 415, English感染症 RA患者の疾患活動性に対するtrimethoprim-sulfamethoxazoleの効果 ANSWER縦断的コホート研究(Infection The effects of trimethoprim-sulfamethoxazole on disease activity in patients with RA: ANSWER longitudinal cohort study)[Refereed]
- (一社)日本リウマチ学会, Mar. 2018, 日本リウマチ学会総会・学術集会プログラム・抄録集, 62回, 492 - 492, Japanese多発性筋炎・皮膚筋炎3 抗MDA5抗体陽性間質性肺疾患の長期臨床経過[Refereed]
- (一社)日本リウマチ学会, Mar. 2018, 日本リウマチ学会総会・学術集会プログラム・抄録集, 62回, 517 - 517, Japanese関節リウマチの治療評価と予測1 血清メタボローム解析による関節リウマチ患者の生物学的製剤治療反応性の予測バイオマーカーの同定[Refereed]
- (一社)日本リウマチ学会, Mar. 2018, 日本リウマチ学会総会・学術集会プログラム・抄録集, 62回, 525 - 525, Japanese血管炎5:大型血管炎症例集積研究 高安動脈炎における当院での治療成績とトシリズマブの有効性についての検討[Refereed]
- (一社)日本リウマチ学会, Mar. 2018, 日本リウマチ学会総会・学術集会プログラム・抄録集, 62回, 760 - 760, Japanese仙腸関節炎に対してTNFα阻害薬で加療中に消化管穿孔で顕在化した腸管型ベーチェット病の一例[Refereed]
- (一社)日本リウマチ学会, Mar. 2018, 日本リウマチ学会総会・学術集会プログラム・抄録集, 62回, 824 - 824, Japanese多発微小肝動脈瘤を伴った顕微鏡学的多発血管炎の一例[Refereed]
- Dec. 2017, CYTOKINE, 100, 125 - 125, EnglishCD11b(+)Gr1(dim) tolerogenic dendritic dell-like cells are expanded in interstitial lung disease in SKG miceSummary international conference
- Oct. 2017, ARTHRITIS & RHEUMATOLOGY, 69, EnglishInhibition of the Mechanistic Target of Rapamycin Pathway and Glutaminolysis Facilitates the Expansion of Myeloid-Derived Suppressor Cells and Synergistically Ameliorates Arthritis in SKG MiceSummary international conference
- Oct. 2017, ARTHRITIS & RHEUMATOLOGY, 69, EnglishCD11b+Gr1dim tolerogenic Dendritic Cell-like Cells Suppress the Progression of Interstitial Lung Disease in SKG MiceSummary international conference
- 日本臨床免疫学会, Aug. 2017, 日本臨床免疫学会会誌, 40(4) (4), 305 - 305, Japaneseシェーグレン症候群による亜急性感覚失調性ニューロパチーの1例[Refereed]
- 日本臨床免疫学会, Aug. 2017, 日本臨床免疫学会会誌, 40(4) (4), 308 - 308, Japanese炎症性筋疾患に合併する間質性肺疾患における血清マーカーの推移[Refereed]
- Jun. 2017, ANNALS OF THE RHEUMATIC DISEASES, 76, 487 - 488, EnglishSummary international conference
- Jun. 2017, ANNALS OF THE RHEUMATIC DISEASES, 76, 507 - 508, EnglishSummary international conference
- Jun. 2017, ANNALS OF THE RHEUMATIC DISEASES, 76, 699 - 699, EnglishSummary international conference
- (一社)日本リウマチ学会, Mar. 2017, 日本リウマチ学会総会・学術集会プログラム・抄録集, 61回, 545 - 545, Japanese骨粗鬆症と骨代謝/変形性関節症・軟骨 ステロイド骨粗鬆症(GIO)に対するデノスマブの有効性 2年間の使用成績[Refereed]
- Oct. 2016, ARTHRITIS & RHEUMATOLOGY, 68, EnglishDual Effect of 3-Bromopyruvate on Both Th17 and Treg Cell Differentiation and Dendritic Cell Activation Ameliorates Autoimmune Arthritis in MiceSummary international conference
- Oct. 2016, ARTHRITIS & RHEUMATOLOGY, 68, EnglishGlutamine Metabolism Plays a Crucial Role in the Pathogenesis of Rheumatoid ArthritisSummary international conference
- Oct. 2016, ARTHRITIS & RHEUMATOLOGY, 68, EnglishCD11b+Gr1dimcells, Which Are Induced By GM-CSF Produced By Th17 and Group3 Innate Lymphoid Cell, May Facilitate the Progression of Pneumonitis in SKG MiceSummary international conference
- Oct. 2016, ARTHRITIS & RHEUMATOLOGY, 68, EnglishImpact of Socioeconomic Status on Disease Outcomes in Japanese Patients with Rheumatoid Arthritis Under the Japanese National Insurance SystemSummary international conference
- 日本臨床免疫学会, Aug. 2016, 日本臨床免疫学会会誌, 39(4) (4), 376 - 376, Japanese解糖系代謝阻害剤3-ブロモピルビン酸はマウス関節炎を抑制する[Refereed]
- 日本臨床免疫学会, Aug. 2016, 日本臨床免疫学会会誌, 39(4) (4), 410 - 410, JapaneseSKGマウス肺病変の進展に伴って増加するCD11b+Gr1 dimcellはGM-CSFによって誘導される[Refereed]
- Jun. 2016, ANNALS OF THE RHEUMATIC DISEASES, 75, 170 - 170, EnglishSummary international conference
- Jun. 2016, ANNALS OF THE RHEUMATIC DISEASES, 75, 113 - 113, EnglishSummary international conference
- Jun. 2016, ANNALS OF THE RHEUMATIC DISEASES, 75, 963 - 963, EnglishSummary international conference
- Jun. 2016, ANNALS OF THE RHEUMATIC DISEASES, 75, 413 - 414, EnglishSummary international conference
- (一社)日本リウマチ学会, Mar. 2016, 日本リウマチ学会総会・学術集会プログラム・抄録集, 60回, 344 - 344, Japaneseリウマチ性疾患の基礎研究 SKGマウス肺病変の進展に伴って増加するCD11b+Gr1dim cellはGM-CSFによって誘導される[Refereed]
- (一社)日本リウマチ学会, Mar. 2016, 日本リウマチ学会総会・学術集会プログラム・抄録集, 60回, 361 - 361, Japaneseベーチェット病 特殊型ベーチェット病に対するTNF阻害剤の有効性[Refereed]
- (一社)日本リウマチ学会, Mar. 2016, 日本リウマチ学会総会・学術集会プログラム・抄録集, 60回, 447 - 447, Japanese関節リウマチの治療評価と予測 疼痛評価VASが高い患者の健康状態全般評価VASは過小申告されていることがある(ROCKoコホート研究から)[Refereed]
- (一社)日本リウマチ学会, Mar. 2016, 日本リウマチ学会総会・学術集会プログラム・抄録集, 60回, 456 - 456, Japanese関節リウマチの治療 QOL 治療目標に到達した関節リウマチ患者の主観的幸福度は、一般的な日本人より高い(ROCKoコホート研究から)[Refereed]
- (一社)日本リウマチ学会, Mar. 2016, 日本リウマチ学会総会・学術集会プログラム・抄録集, 60回, 468 - 468, Japaneseリウマチ性疾患の疫学 関節リウマチ患者における社会経済的要因が疾患活動性、日常生活動作に与える影響の検討(ROCKoコホート研究から)[Refereed]
- Oct. 2015, ARTHRITIS & RHEUMATOLOGY, 67, 3 - 8, English, International magazine[Refereed]Summary international conference
- Oct. 2015, ARTHRITIS & RHEUMATOLOGY, 67, EnglishTaurine As a Biomarker for Prediction of Response to Biologic Therapy in Rheumatoid ArthritisSummary international conference
- Oct. 2015, ARTHRITIS & RHEUMATOLOGY, 67, EnglishHigh Serum IgG4 Concentration Is a Risk Factor for Relapse in IgG4-Related DiseaseSummary international conference
- (一社)日本リウマチ学会, Mar. 2015, 日本リウマチ学会総会・学術集会プログラム・抄録集, 59回, 336 - 336, Japaneseリウマチ性疾患の基礎研究 JAK1/3阻害がMyeloid-derived suppressor cellを誘導し、SKGマウス関節炎を抑制する[Refereed]
- (一社)日本リウマチ学会, Mar. 2015, 日本リウマチ学会総会・学術集会プログラム・抄録集, 59回, 369 - 369, Japaneseその他の膠原病 脊椎関節炎51例の臨床的検討[Refereed]
- (一社)日本リウマチ学会, Mar. 2015, 日本リウマチ学会総会・学術集会プログラム・抄録集, 59回, 573 - 573, Japanese閉経後女性および40歳以上の男性にステロイド大量療法を行う際、ビスフォスフォネート製剤の脆弱性骨折の予防効果は不十分である[Refereed]
- (一社)日本リウマチ学会, Mar. 2015, 日本リウマチ学会総会・学術集会プログラム・抄録集, 59回, 657 - 657, Japanese原発性シェーグレン患者における睡眠障害の検討[Refereed]
- 日本臨床免疫学会, Aug. 2014, 日本臨床免疫学会会誌, 37(4) (4), 379 - 379, Japanese当院におけるIgG4関連疾患25例の再燃リスクについての検討[Refereed]
- Jun. 2014, ANNALS OF THE RHEUMATIC DISEASES, 73, 763 - 763, EnglishSummary international conference
- Jun. 2014, ANNALS OF THE RHEUMATIC DISEASES, 73, 524 - 525, EnglishSummary international conference
- Feb. 2014, JOURNAL OF BONE AND MINERAL RESEARCH, 29, S462 - S462, EnglishIneffective fracture prevention by bisphosphonate in patients undergoing high dose glucocorticoid therapy with a FRAX ten year probability greater than 5.8%.Summary international conference
- Oct. 2013, ARTHRITIS AND RHEUMATISM, 65, S895 - S895, EnglishThe Effect Of a Novel System Of Insoles Using Styrene Foam Beads On Foot Deformities In RA PatientsSummary international conference
- (一社)日本リウマチ学会, Mar. 2013, 日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, 57回・22回, 535 - 535, Japaneseベーチェット病113例の臨床的特徴[Refereed]
- (一社)日本リウマチ学会, Mar. 2013, 日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, 57回・22回, 599 - 599, Japanese肥厚性硬膜炎を合併した肉芽腫性多発血管炎(GPA)の治療中に髄液漏を来した1例[Refereed]
- (一社)日本リウマチ学会, Mar. 2013, 日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, 57回・22回, 673 - 673, Japaneseリツキシマブ、クリオフィルトレーションを含む集学的治療にて治療しえた難治性クリオグロブリン血管炎の1例[Refereed]
- 2013, 日本臨床リウマチ学会プログラム・抄録集, 28thサラゾスルファピリジン(SASP)単剤治療でde novo B型肝炎を来した関節リウマチ(RA)の1例
- Oct. 2012, ARTHRITIS AND RHEUMATISM, 64(10) (10), S836 - S836, EnglishEffect of Adalimumab On the Serum Level of Undercarboxylated Osteocalcin (ucOC), Bone Biochemical Markers and Bone Mineral DensitySummary international conference
- Oct. 2012, ARTHRITIS AND RHEUMATISM, 64(10) (10), S186 - S186, EnglishTNF alpha Modulates the Expression of Circadian Clock Gene, Per2, Via D-Box Motif in the Promoter Region in Rheumatoid Synovial Cells.[Refereed]Summary international conference
- (一社)日本リウマチ学会, 19 Mar. 2012, 日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, 56th-21st, 534 - 534, Japaneseアダリムマブ使用下における血清低カルボキシル化オステオカルシン濃度の変化について
- (一社)日本リウマチ学会, 19 Mar. 2012, 日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, 56th-21st, 579 - 579, Japanese関節リウマチ患者に対するトシリズマブの治療成績
- 2012, 日本臨床リウマチ学会プログラム・抄録集, 27th, 126, Japanese関節リウマチ寛解達成のための最適なトシリズマブ導入時期の検討
- 2011, 日本臨床リウマチ学会プログラム・抄録集, 26th, 138, Japanese関節リウマチ患者に対するトシリズマブの治療成績―寛解導入に関わる因子の検討―
- (一社)日本リウマチ学会, 19 Mar. 2010, 日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, 54th-19th, 699 - 699, Japanese当センターにおける新規関節リウマチ患者に対する治療成績
- (一社)日本リウマチ学会, 19 Mar. 2010, 日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, 54th-19th, 616 - 616, Japaneseインターフェロン治療中断後に,ポリニューロパチーにて発症したクリオグロブリン血症の一例
- (一社)日本リウマチ学会, 19 Mar. 2010, 日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, 54th-19th, 587 - 587, Japanese当センターにおける関節リウマチ患者に対するアダリムマブの使用成績
- (一社)日本リウマチ学会, 19 Mar. 2010, 日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, 54th-19th, 540 - 540, Japanese関節リウマチ患者における睡眠障害
- 第67回日本臨床検査医学会学術集会, Nov. 2020, Japanese当院における抗DNA抗体検出法についての検討 -Farr法とCLEIA法の比較について-Oral presentation
- 第22回日本骨粗鬆症学会, Oct. 2020, Japanese異所性石灰化病変を合併した全身性エリテマトーデス患者に対してテリパラチドにより異所 性石灰化と骨粗鬆症を同時に治療しえた一例Oral presentation
- ARTHRITIS & RHEUMATOLOGY, Oct. 2020, English, WILEYResolvin D5 Modulates Th17/Treg Cell Differentiation and Suppresses Osteoclastogenesis
- ARTHRITIS & RHEUMATOLOGY, Oct. 2020, English, WILEYSoluble Guanylate Cyclase Reduced the Gastrointestinal Fibrosis in Bleomycin-induced Mouse Model of Systemic Sclerosis
- ARTHRITIS & RHEUMATOLOGY, Oct. 2020, English, WILEYCombined Inhibition of Autophagy and Glutamine Metabolism Suppresses Cell Growth of RA Synoviocytes and Ameliorates Arthritis in SKG Mice
- 第66回 日本臨床検査医学会学術集会, Nov. 2019, JapaneseRCPC2[Invited]Nominated symposium
- 第66回 日本臨床検査医学会学術集会, Nov. 2019, Japanese当院における全身性エリテマトーデスによる血球貪食症候群の検討Oral presentation
- ARTHRITIS & RHEUMATOLOGY, Oct. 2019, English, WILEYThe Comparative Efficacy of Pneumocystis Pneumonia Prophylactic Regimens in Patients with Connective Tissue Diseases Receiving Prolonged High-dose Glucocorticoids
- 臨床病理, Oct. 2019, Japanese, 日本臨床検査医学会当院における全身性エリテマトーデスによる血球貪食症候群の検討
- 臨床病理, Oct. 2019, Japanese, 日本臨床検査医学会抗核抗体検査において抗細胞質抗体の細分類が有用であった2症例
- ANNALS OF THE RHEUMATIC DISEASES, Jun. 2019, English, BMJ PUBLISHING GROUPPREDICTION OF RECURRENCE AFTER DISCONTINUATION OF ADALIMUMAB BY USING ULTRASOUND ASSESSMENT -THE PROUD STUDY-
- 日本リウマチ学会総会・学術集会プログラム・抄録集, Mar. 2019, Japanese, (一社)日本リウマチ学会ANCA関連血管炎の寛解導入療法中に、リツキシマブに起因する急性血小板減少が疑われた3例
- 日本リウマチ学会総会・学術集会プログラム・抄録集, Mar. 2019, Japanese, (一社)日本リウマチ学会抗TIF1γ抗体陽性皮膚筋炎症例の臨床的特徴
- 日本リウマチ学会総会・学術集会プログラム・抄録集, Mar. 2019, Japanese, (一社)日本リウマチ学会関節リウマチとSLEを合併した強皮症オーバーラップ症候群の一例
- 日本リウマチ学会総会・学術集会プログラム・抄録集, Mar. 2019, Japanese, (一社)日本リウマチ学会SLEとの鑑別を要した自己免疫性溶血性貧血と特発性膜性腎症の合併例
- 日本リウマチ学会総会・学術集会プログラム・抄録集, Mar. 2019, Japanese, (一社)日本リウマチ学会当施設におけるニューモシスティス肺炎に対する治療の実態
- 日本リウマチ学会総会・学術集会プログラム・抄録集, Mar. 2019, Japanese, (一社)日本リウマチ学会アダリムマブの寛解後休薬についての検討
- 内科学会 第223回近畿地方会, Mar. 2019, Japanese, 京都, Domestic conference胸膜炎を呈した強皮症の1例Oral presentation
- 内科学会 第223回近畿地方会, Mar. 2019, Japanese, 京都, Domestic conferenceNPSLEとTMAの合併に対して、ステロイドパルス、血漿交換、シクロホスファミドパルスを併用し早期に改善しえた1例Oral presentation
- 第222回日本内科学会近畿地方会, Dec. 2018, Japanese, 大阪, Domestic conference顔面から頸部の表在感覚障害をきたしたIgA血管炎の1例Oral presentation
- 第222回日本内科学会近畿地方会, Dec. 2018, Japanese, 大阪, Domestic conferenceサイトメガロウイルス食道炎・胃炎による門脈ガス血症を来した多発血管炎性肉芽腫症Oral presentation
- 第46回 日本臨床免疫学会総会, Nov. 2018, Japanese, 長野, Domestic conference顔面から頸部の表在感覚障害をきたしたIgA血管炎の1例Public symposium
- 第46回 日本臨床免疫学会総会, Nov. 2018, Japanese, 長野, Domestic conferenceサイトメガロウイルス食道炎・胃炎による門脈ガス血症を来した多発血管炎性肉芽腫症Poster presentation
- American College of Rheumatology 82nd Annual Scientific Meeting., Nov. 2018, English, シカゴ, International conferenceTofacitinib facilitates the expansion of myeloid-derived suppressor cells and ameliorates interstitial lung disease in SKG mice.Poster presentation
- American College of Rheumatology 82nd Annual Scientific Meeting., Nov. 2018, English, シカゴ, International conferenceCombined inhibition of mechanistic target of rapamycin and glutamine metabolism inhibits CD4 T cell proliferation and Th17 differentiation, facilitates the expansion of myeloid-derived suppressor cells, and synergistically ameliorates arthritis in SKG micPoster presentation
- 日本内科学会 第221回近畿地方会, Sep. 2018, Japanese, 大阪, Domestic conference悪性関節リウマチの急性期に発作性心房細動・洞不全症候群・僧帽弁逆流症の一過性増悪を認め、ステロイド投与にて改善が得られた1例Oral presentation
- Annual European Congress of Rheumatology, Jun. 2018, English, アムステルダム, International conferenceThe effects of trimethoprim-sulfamethoxazole on disease activity in patients with rheumatoid arthritis.Poster presentation
- Annual European Congress of Rheumatology, Jun. 2018, English, アムステルダム, International conferenceDifferences in clinical courses and serum markers of interstitial lung disease associated with anti-aminoacyl-transfer rna synthetase antibody and anti-melanoma differentiation-associated gene 5 antibody-positive polymyositis/dermatomyositis.Poster presentation
- 第62回日本リウマチ学会総会・学術集会プログラム, Apr. 2018, Japanese, 東京, Domestic conference多発性小肝動脈瘤を伴った顕微鏡学的多発血管炎の一例Poster presentation
- 第62回日本リウマチ学会総会・学術集会プログラム, Apr. 2018, Japanese, 東京, Domestic conference仙腸関節炎に対してTNFα阻害薬で加療中に消化管穿孔で顕在化した腸管型ベーチェット病の一例Poster presentation
- 第62回日本リウマチ学会総会・学術集会プログラム, Apr. 2018, English, 東京, Domestic conferenceInhibition of mTOR pathway and glutaminolysis facilitates the expansion of myeloidderived suppressor cells and synergistically ameliorates arthritis in SKG miceOral presentation
- 第62回日本リウマチ学会総会・学術集会プログラム, Apr. 2018, English, 東京, Domestic conferenceCombined inhibition of mTOR and glutamine metabolism inhibits CD4+ T cell proliferation and Th17 differentiation, facilitates the expansion of myeloid-derived suppressor cells, and synergistically ameliorates arthritis in SKG mice.Public symposium
- 第465回日本皮膚科学会大阪地方会, Feb. 2018, Japanese, 大阪地方会, 大阪, Domestic conferenceHIV感染症に合併した梅毒性乾癬の1例Oral presentation
- 第48回神戸免疫・膠原病懇話会, Jan. 2018, Japanese, 神戸免疫・膠原病懇話会, 神戸, Domestic conference腎生検所見が診断の決め手となった発熱・腎機能障害の一例Oral presentation
- 第45回日本臨床免疫学会総会, Sep. 2017, Japanese, 日本臨床免疫学会, 東京, Domestic conference炎症性筋疾患に合併する間質性肺疾患における血清マーカーの推移Poster presentation
- 第45回日本臨床免疫学会総会, Sep. 2017, Japanese, 日本臨床免疫学会, 東京, Domestic conferenceシェーグレン症候群による亜急性感覚失調性ニューロパチーの1例Poster presentation
- 第38回日本炎症・再生医学会, Jul. 2017, Japanese, 日本炎症・再生医学会, 大阪, Domestic conferenceSKGマウスの間質性肺炎ではユニークな免疫寛容性樹状細胞が誘導されるPoster presentation
- 第61回日本リウマチ学会総会・学術集会, Apr. 2017, Japanese, 日本リウマチ学会, 福岡, Domestic conference骨粗鬆症と骨代謝/変形性関節症・軟骨ステロイド骨粗鬆症(GIO)に対するデノスマブの有効性 2年間の使用成績Public symposium
- Annals of the Rheumatic Diseases, Jun. 2016THU0611 Subjective Well-Being of Japanese RA Patients Who Reach Treatment Target Is Higher than The Japanese Average
- Annals of the Rheumatic Diseases, Jun. 2016AB0192 Some of The Painful RA Patients Underrate Global Health VAS at Hospitals
- Annals of the Rheumatic Diseases, Jun. 2016OP0297 Knockout of Endothelin Type B Receptor Signaling Attenuates Bleomycin-Induced Skin Sclerosis in Mice
- Annals of the Rheumatic Diseases, Jun. 2016OP0150 3-Bromopyruvate Ameliorates Autoimmune Arthritis by Exerting A Dual Effect on Both Th17 and Treg Cell Differentiation and Dendritic Cell Activation
- The 56th Annual Scientific Meeting, Apr. 2012The effect of adalimumab (ADA) on the serum levels of ucOC in the patients with rheumatoid arthritis.
- 日本学術振興会, 科学研究費助成事業, 若手研究, 神戸大学, 01 Apr. 2019 - 31 Mar. 2023免疫担当細胞の細胞代謝を利用した自己免疫疾患の新規治療申請者らは2019年度の科学研究費申請において、T細胞の細胞代謝と線維化の関係を明らかにするため、実験を計画した。計画書において、申請者らは申請時点において、ブレオマイシン誘導性間質性肺炎モデルにおいて、代謝阻害剤X, Yについて、肺における炎症を改善させることを予備実験で提示していた。しかし、ブレオマイシン誘導性間質性肺炎において、炎症と同時に治療対象となる線維化については未だ代謝阻害剤の効果は未知数であった。特に、難病とされるヒトの全身性強皮症において、炎症を止めるとされる副腎ホルモン剤などの治療が線維化になんら効果がなく、予後改善効果に乏しいことが知られている。従って、代謝阻害剤が炎症スコアを改善せしめたとしても、実際に間質性肺炎による肺の線維化を止めることを示すことが何より重要である。申請者らは2019年度にマウスでの実験を行い、炎症スコアと同様に代謝阻害剤X, Yは線維化スコアを改善せしめることを立証した。具体的にはブレオマイシン誘導性間質性肺炎モデルマウスを用い、対照群、代謝阻害剤X, Y, およびXとYの併用群と4群に分けて、実験を行った。X単独、Y単独群は有意差をもって対照群より線維化が改善していた。また、実験の目的にある細胞代謝はいくつかの経路が相互作用している。XとYは別の経路の代謝阻害効果を有するが、併用により相乗効果があることを申請者らは示した。今後は細胞代謝阻害剤によりT細胞などの免疫担当細胞がどのように変化したのか詳細に検討していく予定である。具体的には実験で得られた検体でreal-time PCRで線維化関連のmRNA発現を確認し、免疫組織染色で免疫担当細胞がどのように細胞代謝阻害剤により変化したか検討していく方針である。また、フローサイトメトリーを行い免疫担当細胞のphenotypeの変化なども解析していく方針である。